Compare CKX & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | LIXT |
|---|---|---|
| Founded | 1930 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 20.5M |
| IPO Year | 1998 | N/A |
| Metric | CKX | LIXT |
|---|---|---|
| Price | $10.45 | $4.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.8K | ★ 85.7K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.14 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $897,333.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.66 | $0.64 |
| 52 Week High | $14.00 | $6.26 |
| Indicator | CKX | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 47.20 |
| Support Level | $8.66 | $3.53 |
| Resistance Level | $10.39 | $4.80 |
| Average True Range (ATR) | 0.33 | 0.43 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 80.80 | 46.53 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. CKX has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Surface segment. Geographically, it generates all of its revenue from the United States of America.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.